Evar Fast-Trackは,安全で費用対効果の高いプロトコルを実装しています
Rita Calviño López-Villalta1, Nilo Javier Mosquera Arochena1
1Hospital Clínico Santiago de Compostela, A Coruña, Spain, Vascular Surgery Department.
Portuguese journal of cardiac thoracic and vascular surgery
|February 20, 2026
まとめ
選択性血管内 aneurysm 修復 (EVAR) のためのファストトラックプロトコルの実装は,入院とコストを大幅に削減します. このアプローチは安全で,有害事象や再入院の増加はなく,潜在的な標準的なケアとなっています.
科学分野:
- 血管外科 血管外科
- 健康経済学 医療経済学
- 患者管理についてです.
背景:
- 選択的内血管動脈瘤修復 (EVAR) は一般的な手順です.
- 患者の退院プロトコルの最適化は,効率と費用対効果のために不可欠です.
- 迅速なプロトコルの評価は,手術後のケアにおける改善を特定することができます.
研究 の 目的:
- 選択的なEVARを受ける患者のための急速退院プロトコルの費用対効果と安全性を評価する.
- 標準入院と高速プロトコルで管理された患者のアウトカムを比較する.
主な方法:
- 選択的EVARを受けた83人の患者の遡及的分析.
- 標準入院時のファストトラックグループ (40人の患者) と対照グループ (43人の患者) の比較.
- データ収集には,滞在期間,費用,再介入率,有害事象,および30日と6ヵ月後の再入院が含まれていました.
主要な成果:
- 急速治療群は,病院での入院期間が大幅に短縮 (2.3 vs 3.7日) され,蘇生ユニットでのモニタリングの必要性が減少しました.
- 加速治療群では,二次介入 (12.5%対23.3%) と再入院率が低いことが観察されました.
- 患者"人当たりの総コスト削減は,平均1936.05ユーロで,ファスト・トラックグループでは1403.29ユーロ対3339.34ユーロであった.
結論:
- 選択的なEVARのための急速なプロトコルは,入院期間を効果的に短縮し,手術後の費用を削減します.
- このプロトコルは,有害事象や再入国率を増加させない.
- 迅速なEVARの導入は,適格な患者にとって標準的な慣行と見なされるべきである.
関連する概念動画
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
38
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
38
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
28
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
28
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
246
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
246
01:18Effects of EDTA on End-Point Detection Methods
691
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
691